On page 3215, a conflict-of-interest disclosure was omitted and should read, “R.S. has an investigator-initiated grant from Takeda Pharmaceuticals for the ATHN 9 study and is a local principal investigator for the PEGylated Recombinant FVIII (BAX 855) previously untreated patients study.” The error has been corrected in the published article.